{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-028629","form_type":"8-K","ticker":"ANEB","cik":"0001815974","company_name":"Anebulo Pharmaceuticals, Inc.","filed_at":"2024-07-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.631559+00:00","generated_at":"2026-05-31T18:36:15.529275+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Anebulo awarded up to $1.9M NIDA grant for IV selonabant development","bullets":["Grant from NIDA/NIH up to ~$1.9M over two years for IV selonabant as emergency treatment for acute cannabis-induced toxicities.","Initial tranche $0.9M awarded; second tranche ~$1M subject to milestone achievements.","Program targets pediatric cannabis-induced CNS depression, a serious unmet medical need.","CEO notes grant validates progress and supports IV formulation clinical testing."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-028629","json":"https://secwatch.observer/filing/0001493152-24-028629.json","markdown":"https://secwatch.observer/filing/0001493152-24-028629.md","text":"https://secwatch.observer/filing/0001493152-24-028629.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815974/000149315224028629/0001493152-24-028629-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815974/000149315224028629/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T18:36:15.529275+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}